ARMP Armata Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ARMP

Price (delayed)

$1.7

Market cap

$61.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$89.45M

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is ...

Highlights
The revenue is up by 23% year-on-year
ARMP's gross profit is up by 23% year-on-year
The equity has grown by 42% YoY but it has contracted by 21% from the previous quarter
The company's quick ratio has shrunk by 81% QoQ and by 65% YoY
The company's net income has shrunk by 59% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.armatapharma.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of ARMP
Market
Shares outstanding
36.14M
Market cap
$61.45M
Enterprise value
$89.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.24
Earnings
Revenue
$5.51M
EBIT
-$36.92M
EBITDA
-$36.03M
Free cash flow
-$34.69M
Per share
EPS
-$1.08
Free cash flow per share
-$1.01
Book value per share
$1
Revenue per share
$0.16
TBVPS
$2.69
Balance sheet
Total assets
$95.83M
Total liabilities
$59.75M
Debt
$48.82M
Equity
$36.08M
Working capital
$2.17M
Liquidity
Debt to equity
1.35
Current ratio
1.09
Quick ratio
0.84
Net debt/EBITDA
-0.78
Margins
EBITDA margin
-654%
Gross margin
100%
Net margin
-670.2%
Operating margin
-670.8%
Efficiency
Return on assets
-37.2%
Return on equity
-75.2%
Return on invested capital
-41.5%
Return on capital employed
-52%
Return on sales
-670.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARMP stock price

How has the Armata Pharmaceuticals stock price performed over time
Intraday
5.59%
1 week
2.41%
1 month
-34.11%
1 year
-67.86%
YTD
37.1%
QTD
37.1%

Financial performance

How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$5.51M
Gross profit
$5.51M
Operating income
-$36.95M
Net income
-$36.92M
Gross margin
100%
Net margin
-670.2%
The company's net income has shrunk by 59% YoY and by 13% QoQ
Armata Pharmaceuticals's operating income has shrunk by 55% YoY and by 13% QoQ
The company's net margin fell by 30% YoY and by 12% QoQ
The company's operating margin fell by 26% YoY and by 12% QoQ

Growth

What is Armata Pharmaceuticals's growth rate over time

Valuation

What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.7
P/S
10.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.24
Armata Pharmaceuticals's EPS has decreased by 13% YoY and by 4.9% QoQ
The equity has grown by 42% YoY but it has contracted by 21% from the previous quarter
ARMP's P/B is 33% below its 5-year quarterly average of 2.4 and 33% below its last 4 quarters average of 2.4
ARMP's price to sales (P/S) is 57% lower than its last 4 quarters average of 23.1
The revenue is up by 23% year-on-year

Efficiency

How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's return on sales has decreased by 30% YoY and by 12% QoQ
ARMP's return on invested capital is up by 15% year-on-year but it is down by 11% since the previous quarter
Armata Pharmaceuticals's ROA has increased by 14% YoY but it has decreased by 6% from the previous quarter
The company's return on equity rose by 9% YoY but it fell by 7% QoQ

Dividends

What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARMP.

Financial health

How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 60% higher than its total liabilities
The company's quick ratio has shrunk by 81% QoQ and by 65% YoY
ARMP's current ratio has dropped by 77% since the previous quarter and by 65% year-on-year
The company's debt is 35% higher than its equity
ARMP's debt to equity has soared by 55% since the previous quarter but it is down by 10% year-on-year
The equity has grown by 42% YoY but it has contracted by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.